Tumour growth kinetics assessment: Added value to RECIST in cancer patients treated with molecularly targeted agents

British Journal of Cancer

Volumn 106, Issue 5, 2012, Pages 854-857

  Le Tourneau, C ^a,b   Servois, V ^a   Dieras V ^a   Ollivier, L ^a   Tresca, P ^a   Paoletti, X ^a,b  

^a INSTITUT CURIE   (France)

^b INSERM U900   (France)

Author keywords

methodology; molecularly targeted agents; oncology trials; RECIST; response assessment; tumour growth kinetics

Indexed keywords

MOLECULAR THERAPY AGENT;

ARTICLE; BREAST ADENOCARCINOMA; CANCER PATIENT; COLORECTAL CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOMA; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS; TREATMENT OUTCOME;

EID: 84857786205     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.10     Document Type: Article

References (16)

1. Amoroso V, Pittiani F, Grisanti S, Valcamonico F, Simoncini E, Ferrari VD, Marini G (2007) Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteria. BMC Cancer 7: 94
2. Buyse M, Quinaux E, Hendlisz A, Golfinopoulos V, Tournigand C, Mick R (2011) Progression-free survival ratio as end point for Phase II trials in advanced solid tumors. J Clin Oncol 29: 451-452
3. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA, Powers J, Seymour L, Laurie SA (2009) Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 27: 404-410
4. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093-1103 (Pubitemid 44275331)
5. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247
6. Gomez-Roca CA, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, Bahleda R, Ferté C, Massard C, Soria JC (2011) Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer 47: 2512-2516
7. Hales RK, Banchereau J, Ribas A, Tarhini AA, Weber JS, Fox BA, Drake CG (2010) Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol 21: 1944-1951
8. Imkampe A, Bendall S, Bates T (2007) The significance of the site of recurrence to subsequent breast cancer survival. Eur J Surg Oncol 33: 420-423 (Pubitemid 46586085)
9. Le Tourneau C, Razak AR, Gan HK, Pop S, Diéras V, Tresca P, Paoletti × (2011) Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature. Eur J Cancer 47: 1468-1475
10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390
11. Messiou C, Cook G, Reid AH, Attard G, Dearnaley D, de Bono JS, de Souza NM (2011) The CT flare response of metastatic bone disease in prostate cancer. Acta Radiol 52: 557-561
12. Mick R, Crowley JJ, Carroll RJ (2000) Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 21: 343-359 (Pubitemid 30456294)
13. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505-2512 (Pubitemid 46630627)
14. Von Hoff DD (1998) There are no bad anticancer agents, only bad clinical trial designs-twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 4: 1079-1086 (Pubitemid 28213317)
15. Von Hoff DD, Stephenson Jr JJ, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R (2010) Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28: 4877-4883
16. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41: 1751-1757 (Pubitemid 41132637)